Doctor who found Omicron variant says symptoms are mild, media is overreacting


Chairwoman of the South African Medical Association and private practitioner Dr. Angelique Coetzee, one of the doctors who first identified the Omicron variant of COVID-19, says that the government and media are overreacting to an even milder strain of COVID.

“Looking at the mildness of the symptoms that we are seeing, currently there is no reason for panicking, as we don’t see severely ill patients,” explained Coetzee in an interview with Reuters.

“I also checked with the hospitals, some of the hospitals in my area, and one of the biggest hospitals that have one patient currently that’s COVID positive on a ventilator, and they don’t even know whether it’s COVID or whether it’s Delta, or whether it is Omicron related.”

“We acknowledge that it might change going forward,” Coetzee continues, “but the hype that’s been created out currently out there in the media and worldwide doesn’t correlate with the clinical picture. And it doesn’t warrant to just cut us off from any travelling and ban South Africa as if we are the variants in the whole process.”

“It should not be like that.”

Coetzee further details the discovery of the new variant, saying that she hadn’t seen a COVID patient in months until a few patients came in showing some symptoms consistent and inconsistent with the Delta variant, prompting South African doctors to administer tests.

Again, she stresses that the new symptoms she saw, including excess fatigue, are mild and adds that symptoms are so mild they can be treated at home over a few days.

Moreover, not a single patient diagnosed with the Omicron variant needed to be taken to surgery or ICUs.

Two differences between the Omicron and Deltas variant, which Coetzee notes, is that patients do not report a loss of taste nor significant drops in oxygen levels.

Despite her report, the media has fired up the fearmongering machine, again, pumping out article after article justifying the government’s imposition of travel bans and other restrictions.

Pharmaceutical companies are also preparing for their next cash grab, saying they’ll have a new vaccine ready in three to four months, as some reports suggest the Omicron is resistant to current vaccines.

So, don’t worry. The government will still compel you to get jabbed for an even less-lethal variant of an already mild virus.

Support our work

Share this story

Donate now to keep us on the front lines:

Help Keep your News Free

It's crucial we stay in touch

Big Tech wants to censor us, that’s why you need to stay in touch.

[wpp limit=6 order_by='views']

YOU MIGHT ALSO LIKE THESE...

Trending News

Donald Trump goes after gender ideology in his second speech since narrowly surviving an assassination attempt.

TCS Wire

July 20, 2024

Trending News

The federally-funded Toronto Star, which once wrote “let them die” referring to unvaccinated people, published an article claiming Canadians haven’t lost any freedom.

Alexa Posa

June 21, 2024

Trending News

Liberals admit they never had evidence that COVID vaccines stopped transmission of the virus.

Mike Campbell

June 4, 2024

Trending News

Dutch researchers analyzing data from 47 Western countries have postulated that the most likely cause of 3 million excess deaths between 2020 and 2022 is the COVID vaccine.

TCS Wire

June 4, 2024

Trending News

“I’m on pension. How am I going to pay for that?” asked Liz Diachun from Ontario after being hit with a $40,000 capital gains tax on her gift.

Keean Bexte

May 31, 2024

Trending News

After the COVID vaccines were coerced into about 85% of Canadians, including one that’s since been taken off shelves amid shocking adverse effect admissions, many have wondered if there was a connection between in-flight medical emergencies and the experimental shots that lacked long-term safety data. 

Mike Campbell

May 28, 2024

Want to join the conversation?

Sign up now to be able to like, comment and reply to other members. A full membership to our site includes:

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.